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Abstract
We conducted imputation to the 1000 Genomes Project of four genome-wide association studies 
of lung cancer in populations of European ancestry (11,348 cases and 15,861 controls) and 
genotyped an additional 10,246 cases and 38,295 controls for follow-up. We identified large-effect 
genome-wide associations for squamous lung cancer with the rare variants of BRCA2-K3326X 
(rs11571833; odds ratio [OR]=2.47, P=4.74×10−20) and of CHEK2-I157T (rs17879961; OR=0.38 
P=1.27×10−13). We also showed an association between common variation at 3q28 (TP63; 
rs13314271; OR=1.13, P=7.22×10−10) and lung adenocarcinoma previously only reported in 
Asians. These findings provide further evidence for inherited genetic susceptibility to lung cancer 
and its biological basis. Additionally, our analysis demonstrates that imputation can identify rare 
disease-causing variants having substantive effects on cancer risk from pre-existing GWAS data.
Lung cancer causes over 1 million deaths each year worldwide1. While primarily caused by 
tobacco smoking, studies have also implicated inherited genetic factors in its etiology; 
notably genome-wide association studies (GWAS) in Europeans have consistently identified 
polymorphic variation at 15q25.1 (CHRNA5-CHRNA3-CHRNB4), 5p15.33 (TERT-
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CLPTM1) and 6p21.33 (BAT3-MSH5) as determinants of lung cancer risk2-6. Additionally, 
susceptibility loci for lung cancer at 3q28, 6q22.2, 13q12.12, 10q25.2 and 22q12.2 in Asians 
have been identified through GWAS7-9.
Non-small cell lung cancer (NSCLC) is the commonest lung cancer histology, comprised 
primarily of adenocarcinoma (AD) and squamous cell carcinoma (SQ). These lung cancer 
histologies have different molecular characteristics reflective of differences in etiology and 
carcinogenesis10. Perhaps not surprisingly there is variability in genetic effects on lung 
cancer risk by histology with subtype-specific associations at 5p15.33 (TERT-CLPTM1) for 
AD11,12 and at 9p21 (CDKN2A/CDKN2B)13 and 12q13.33 (RAD52)14 for SQ. In addition 
the 6p21.33 associations are stronger for SQ than AD13.
To identify additional lung cancer susceptibility loci we conducted a meta-analysis of four 
lung cancer GWAS in populations of European ancestry, the MD Anderson Cancer Center 
(MDACC) GWAS; the Institute of Cancer Research (ICR) GWAS; the National Cancer 
Institute (NCI) GWAS and the International Agency for Research on Cancer (IARC) GWAS 
(Online Methods) that were genotyped using either Illumina HumanHap 317, 317+240S, 
370Duo, 550, 610 or 1M arrays (Supplementary Table 1). After filtering the studies 
provided genotypes on 11,348 cases and 15,861 controls (Supplementary Table 1). Prior to 
undertaking meta-analysis of the GWAS, we searched for potential errors and biases in the 
datasets. Quantile-quantile (Q-Q) plots of genomewide association test statistics showed 
minimal inflation rendering substantial cryptic population substructure or differential 
genotype calling between cases and controls unlikely (λ=1.01 to 1.05; Supplementary Figure 
1). To bring genotype data obtained from different arrays into a common platform and 
recover untyped genotypes, we imputed >10 million SNPs using 1000 Genomes Project data 
as reference. Q-Q plots for all SNPs and restricted to rare SNPs (minor allele frequency 
(MAF) <1%) post imputation did not show evidence of substantive over-dispersion 
introduced by imputation (λ=0.99-1.06 and 0.82-1.05 respectively; Supplementary Figure 
1).
Pooling data from each GWAS, we derived joint odds ratios (ORs) and 95% confidence 
intervals (CIs) under a fixed effects model for each SNP and associated per allele P-values. 
To explore the variability in associations according to tumour histology we derived ORs for 
all lung cancer, AD and SQ.
Meta-analysis identified 50 SNPs that showed evidence of an association with either lung 
cancer, AD or SQ (P<5.0×10−6; Figure 1) at loci not previously reported in Europeans 
(Figure 1). 1Mb regions encompassing these 50 SNPs were evaluated for association 
through in silico replication in the Harvard15 and deCODE16 series. Nine of the SNPs within 
these 50 regions showed support for an association (combined P-value <5.0×10−7). 
Genotyping of these nine SNPs was attempted in four additional series, Heidelberg-EPIC 
replication, ICR replication, IARC replication and Toronto replication (Supplementary 
Table 3 (b), Online Methods). rs185577307 could not be genotyped due to repetitive 
sequence. Collectively genotypes are available from 21,594 cases and 54,156 controls, 
providing 80% power to detect a variant with MAF of 0.01 conferring a relative risk of ≥1.5. 
In the combined analysis of all GWAS plus replication series, SNPs mapping to 13q13.1 
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(rs11571833, rs56084662), 22q12.1 (rs17879961) and 3q28 (rs13314271) showed evidence 
for an association, which was statistically significant after adjustment for multiple testing 
(i.e. P<3.0×10−9; Figure 2, Supplementary Table 2). We confirmed the high fidelity of 
imputation by genotyping rs11571833, rs17879961 and rs13314271 in subsets of ICR-
GWAS, IARC-GWAS, NCI-GWAS and MDACC-GWAS (Supplementary Table 3, Online 
Methods). The NCI-GWAS comprised samples from Finland, Italy and the US. The IARC-
GWAS comprised samples from 10 series from Western and Eastern Europe, and the US. 
While adjustment of test statistics for principle components generated on common SNPs had 
been applied to these GWAS, confounding of rare variants in spatially structured 
populations is not necessarily corrected by such methods17. We therefore investigated if 
country of origin had an impact on the associations at 13q13.1 and 22q12.1; the associations 
remained statistically highly significant (Supplementary Table 4).
Both rs11571833 and rs56084662 localizing to 13q13.1, near or within BRCA2, are rare 
SNPs (MAF<0.01), map 103kb apart (32,972,376bps, 32,869,614bps) and are moderately 
correlated (r2=0.45, D′=0.82, based on genotypes from Heidelberg-EPIC, IARC replication, 
ICR-replication and Toronto-replication series; Figure 3). rs11571833 (c.9976A>T) is 
responsible for BRCA2-K3326X whereas rs56084662 is located in the 3′UTR of FRY. While 
the association provided by rs11571833 was substantially stronger than rs56084662 in the 
combined analysis (OR=1.83, P=2.11×10−19 and P=1.88×10−15) conditional analysis based 
on directly genotyped samples in the replication series was consistent with the two SNPs 
tagging the same haplotype. The rs11571833 association is primarily driven by a 
relationship with SQ rather than AD histology (OR=2.47, P=4.74×10−20 and OR=1.47, 
P=4.66×10−4 respectively; Figure 2, Supplementary Table 2). A more significant role for 
BRCA2 in SQ etiology than in AD is reflected in the higher observed mutational frequency 
in respective lung cancers (~6% and 1%18,19). c.9976T has recently been shown to confer a 
1.26-fold increased breast cancer risk20 and previously suggested as a risk factor for 
esophageal and pancreatic cancers21,22. We found no evidence for an association between c.
9976T and lung cancer risk in non-smokers using directly genotyped samples 
(Supplementary Table 3), however these cases comprised <10% of each cohort hence our 
power to demonstrate a relationship was limited. Previous analysis of families carrying 
highly penetrant BRCA2 mutations have either found no evidence for any excess or a 
reduced lung cancer risk in carriers23,24. A possible explanation for these observations is 
that members of studied breast-ovarian cancer families tend to smoke less than the general 
population24.
The rad51-brca2 interaction is pivotal for brca2-mediated double stranded break repair 
(DSBR) and exon 27 of BRCA2 encodes one of the highly conserved rad51 binding 
domains; homozygous deletion of exon 27 in mice confers susceptibility to tumours 
including lung cancer25. c.9976T leads to the loss of the C-terminal domain of brca2 inviting 
speculation that the SNP is functional. While the deleted region is distal to the rad51 binding 
domain and an impact on nuclear localisation is debated26,27 the nearby mutation at BRCA2 
T3387A interrupts chk2-phosphorylation and abrogates BRCA2-Chk2-Rad51 mediated 
recombination repair28. Alternatively, the association might be a consequence of linkage 
disequilibrium (LD) with another BRCA2 mutation. Studies of breast cancer families with 
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northern European ancestry show the BRCA2 c.6275delTT and c.4889C>G mutations which 
are highly penetrant for breast and ovarian cancer originated on a K3326X haplotype29. To 
gain further insight into a probable genetic basis of the 13q13.1 lung cancer association we 
sequenced germline DNA from 70 lung cancer cases which carried c.9976A>T from the UK 
Genetic Lung Cancer Predisposition Study for c.6275delTT and c.4889C>G mutations. In 
none were c.6275delTT and c.4889C>G mutations identified. Similarly sequencing the 
coding region of BRCA2 identified no clearly pathogenic mutations amongst 13 individuals 
from 1958BC, 11 IARC lung cancer cases or 24 TCGA lung cancer cases carrying c.9976T. 
In Iceland c.9976T is not correlated with the founder BRCA2 mutation p.256_257del 
(999del5) which greatly increases breast and ovarian cancer risk. Paradoxically while c.
9976T is a risk factor for lung cancer in this population the SNP is not associated with breast 
or ovarian cancer risk cancer (Supplementary Table 5). Although in vitro studies have failed 
to demonstrate K3326X affects DNA repair30 our findings raise the possibility K3326X may 
have a direct effect on lung cancer risk. Since somatic mutation of BRCA2 is not associated 
with K3326X carrier status 19 (Supplementary Table 6 (a)) it suggests that any impact the 
SNP has on lung cancer risk is mediated through alternative mechanisms.
The relationship at 22q12.1 between the SNP rs17879961 (c.470T>C) and SQ in the 
combined series (OR=0.38, P=1.27×10−13) validates an association previously reported31,32 
(Figure 2, Supplementary Table 2, Supplementary Table 4). The frequency of rs17879961 
varies significantly between populations with the MAF being ~5% in Eastern Europeans 
(e.g. IARC series) but almost monomorphic in most Northern Europeans. This is likely to 
account for a failure to demonstrate a significant relationship in the ICR, MDACC, Toronto 
and deCODE series which comprise largely Western European populations (Figure 2, 
Supplementary Table 2). rs17879961 is responsible for the I157T missense mutation in 
CHEK2, a cell cycle control gene encoding a pluripotent kinase that can cause arrest or 
apoptosis in response to DNA damage. Acquired mutation of CHEK2 is rarely seen in lung 
cancer and CHEK2-I57T genotype does not appear to correlate with mutation 
(Supplementary Table 6 (a)) raising the possibility that carrier status per se influences cancer 
risk. I157T lies in a functionally important domain of chek2 causing reduced or abolished 
binding of principal substrates. While c.470C increases breast cancer risk33 here c.470C was 
associated with reduced lung cancer risk. A mechanism for the paradoxical associations is 
not immediately apparent. CHEK2 can however have opposite effects on damaged stem 
cells retarding stem cell division until DNA damage is repaired, or activating apoptosis if 
damage cannot be repaired. Although speculative, in the presence of continued DNA 
damage to squamous epithelia by tobacco smoke the normal stem cell defences involving 
chek2 might be attenuated by a reduction in chek2 activity as a result of I151T31. 
Concordant with such a model is that a paradoxically increased lung cancer risk was seen in 
non-smokers (P=0.05), and correlated subgroups of AD and women, albeit based on small 
numbers (Supplementary Table 3).
The association between variation at 3q28 marked by rs13314271 and lung cancer risk was 
restricted to AD (OR=1.13, P=7.22×10−10Figure 2, Supplementary Table 2). rs13314271 
maps within intron 1 of TP63 (Figure 3). Variation at TP63 defined by the intron 1 SNP 
rs4488809, which is in complete LD with rs13314271 (r2=1.00, D′=1.00) is associated with 
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AD in Asians8. Our findings provide robust evidence for the generalisability of a 
relationship between 3q28 variation and AD. A weak association between rs13314271 and 
lung cancer risk was shown in non-smokers (P=0.03; Supplementary Table 3 (b)). TP63 is a 
member of the tumor suppressor TP53 gene family, which is pivotal to cellular 
differentiation and responsiveness to cellular stress34,35. Exposure of cells to DNA damage 
leads to induction of TP63 and both isoforms have the ability to transactivate TP53 target 
genes, hence impacting on cellular responsiveness to DNA damage36. While rs13314271 
does not map to an evolutionary conserved region (ECR), rs7636839 which is correlated 
with rs13314271 and rs4488809 (r2=1.0) maps to an ECR and has predicted enhancer 
activity (Supplementary Table 6 (b)). Moreover, rs4488809 has been shown to be an eQTL 
for p63 in lung tissue37. Although the mechanism by which 3q28 variation affects AD 
development is unknown, accumulation of DNA damage and lack of response to genotoxic 
stress is recognized to contribute to lung carcinogenesis; hence loss of fidelity of repair as a 
consequence of differential TP63 expression is likely to be deleterious.
There was no association between rs11571833, rs17879961 and rs13314271 genotypes and 
cigarette consumption using smoking information on 43,693 Icelandic subjects 
(Supplementary Table 7); in contrast to the 15q25 association and risk of lung cancer.
While there is overlap distinct DNA lesions are ostensibly repaired by different DNA repair 
pathways and the histology specific relationships seen implicate the brca2-chek2-rad52 
DSBR–homologous recombination pathways as a determinant of SQ and defective tp53/tert 
apoptosis-telomerase regulation as a basis of AD risk.
In conclusion, our findings provide further evidence for inherited genetic susceptibility to 
lung cancer and underscore the importance of searching for histology-specific risk variants. 
Our data also provide an important proof of principle that 1000 Genomes imputation can be 
used to detect novel, low frequency-large effect associations, thereby extending the utility of 
pre-existing GWAS data. Notably this has facilated the identification of BRCA2 c.9976T 
which represents by far the stongest genetic association in lung cancer reported so far. For a 
smoker carrying this variant (2% of the population) the risk of developing lung cancer is 
approximately doubled, which may have implications for identifying high risk ever-smoking 
subjects for lung cancer screening. Additionally, study of the effect of PARP inhibition for 
smokers with lung cancer carrying BRCA2 c.9976T may be warranted.
ONLINE METHODS
The study was conducted under the auspices of the Transdisciplinary Research In Cancer of 
the Lung (TRICL) Research Team, which is a part of the Genetic Associations and 
MEchanisms in ONcology (GAME-ON) consortium, and associated with the International 
Lung Cancer Consortium (ILCCO). Tumours from patients were classified as 
adenocarcinomas (AD), squamous carcinomas (SQ), large-cell carcinomas (LCC), mixed 
adenosquamous carcinomas (MADSQ) and other non-small cell lung cancer (NSCLC) 
histologies following either the International Classification of Diseases for Oncology (ICD-
O) or World Health Organisation (WHO) coding. Tumours with overlapping histologies 
were classified as mixed.
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Ethics
All participants provided informed written consent. All studies were reviewed and approved 
by institutional ethics review committees at the involved institutions.
Genome-wide association studies
The meta-analysis was based on data from four previously reported lung cancer GWAS of 
European populations: the MD Anderson Cancer Center lung cancer study (MDACC-
GWAS)3; the UK lung cancer GWAS from the Institute for Cancer Research (ICR-
GWAS)6; the NCI lung cancer GWAS (NCI-GWAS)13 and the IARC lung cancer GWAS 
(IARC-GWAS)2. In each of the studies, SNP genotyping had been performed using Illumina 
HumanHap 317, 317+240S, 370, 550, 610 or 1M arrays (Supplementary Table 1).
IARC-GWAS—The IARC-GWAS2 comprised 3,062 lung cancer cases and 4,455 controls 
derived from five case-control studies: (i) Carotene and Retinol Efficacy Trial (CARET) 
cohort38; (ii) The Central Europe multicenter hospital-based case-control39,40; (iii) The 
hospital-based case-control study from France40; (iv) The hospital based case-control lung 
cancer study from Estonia41,42; and (v) The population-based HUNT2/Tromsø IV lung 
cancer studies43. Patient and control DNAs were derived from EDTA-venous blood 
samples. The lung cancer patients were classified according to ICD-O-3; SQ: 8070/3, 
8071/3, 8072/3, 8074/3; AD: 8140/3, 8250/3, 8260/3, 8310/3, 8480/3, 8560/3, 8251/3, 
8490/3, 8570/3, 8574/3; with tumours with overlapping histologies classified as mixed. 
After applying standardized quality control procedures 2,533 cases and 3,791 controls were 
included in the current analysis (Supplementary Table 1).
NCI-GWAS—Details of the NCI-GWAS have been previously reported. Briefly, the study 
comprised samples from four series: (i) The Environment and Genetics in Lung cancer 
Etiology (EAGLE), a population-based case-control study of 2,100 lung cancer cases and 
2,120 healthy controls enrolled in Italy between 2002 and 200544. Cancers were classified 
according to the ICD-O coding for histology and grading. Histology of ~10% of tumours 
was confirmed by an independent pathologist from NCI. (ii) The Alpha-Tocopherol, Beta-
Carotene Cancer Prevention Study (ATBC), a randomized primary prevention trial of 
29,133 male smokers enrolled in Finland between 1985 and 199345; ICD-O-2 and ICD-O-3 
was used to classify tumours. Cases diagnosed between 1985 and 1999 had histology 
reviewed by at least one pathologist. After 1999, histological coding (ICD-O-2 and ICD-
O-3) was derived from the Finnish Cancer Registry. (iii) The Prostate, Lung, Colon, Ovary 
Screening Trial (PLCO), a randomized trial of 150,000 individuals enrolled in ten U.S. study 
centers between 1992 and 200146; ICD-O-2 was used to classify tumors and quality 
assurance measures included reabstraction of 50 lung cancer diagnoses per year; (iv) The 
Cancer Prevention Study II Nutrition Cohort (CPS-II), a cohort study of approximately 
184,000 individuals enrolled by the American Cancer Society between 1992 and 1993 in 21 
U.S. states of which 109,379 provided a blood (36%) or buccal (64%) sample between 1998 
and 200312,47. Tumour histology was abstracted from Certified Tumor Registrars and coded 
using WHO ICD-O-2 and ICD-O-3. Quality assurance was done by re-abstracting 10% of 
all cancer diagnoses per year. After initial data control, the NCI-GWAS included 5,739 
cases and 5,848 controls; however, an additional 26 cases and 112 controls were excluded 
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due to changes in case status and further quality control filtering. The current meta-analysis 
included 5,713 lung cancer cases and 5,736 controls from the NCI-GWAS (Supplementary 
Table 1).
ICR-GWAS—This comprised 1,952 cases (1,166 male; mean age at diagnosis 57 years, SD 
6) with pathologically confirmed lung cancer ascertained through the Genetic Lung Cancer 
Predisposition Study (GELCAPS) conducted between March 1999 and July 200448. All 
cases were British residents and self-reported to be of European Ancestry. To ensure that 
data and samples were collected from bona fide lung cancer cases and avoid issues of bias 
from survivorship only incident cases with histologically or cytologically (only if not AD) 
confirmed primary disease were ascertained. Tumours from patients were classified 
according to ICD-O3; Specifically, SQ: 8070/3, 8071/3, 8072/3, 8074/3; AD: 8140/3, 
8250/3, 8260/3, 8310/3, 8480/3, 8560/3, 8251/3, 8490/3, 8570/3, 8574/3; with tumours with 
overlapping histologies classified as mixed. Patient DNA was derived from EDTA-venous 
blood samples using conventional methodologies. Genotype frequencies were compared 
with publicly accessible data generated by the UK Wellcome Trust Case-Control 
Consortium 2 (WTCCC2) study49 of individuals from the 1958 British Birth Cohort (58BC) 
and blood service typed using Illumina Human1.2M-Duo Custom_v1 Array BeadChips.
MDACC-GWAS—Cases and controls were ascertained from a case-control study at the 
U.T. M.D. Anderson Cancer Center conducted between 1997 and 20073. Cases were newly 
diagnosed, patients with histologically-confirmed lung cancer presenting at M.D. Anderson 
Cancer and who had not previously received treatment other than surgery. Clinical and 
pathological data were abstracted from patient medical records and lung cancer histology 
was coded according to the major histological groups. Specifically, as per ICD-O-2 these 
groups were, SQ: 8070/3, AD: 8140/3, 8250/3, 8260/3, 8310/3, 8480/3, 8251/3 and 8490/3. 
Only patients with predominantly or wholly AD or SQ cancers were included; those with 
mixed histology or unspecified lung cancers, were excluded from the study. Controls were 
healthy individuals seen for routine care at Kelsey-Seybold Clinics, in the Houston 
Metropolitan area. Controls were frequency matched to cases according to smoking 
behaviour, age in 5-year categories, ethnicity, and sex. Former smoking controls were 
further frequency matched to former smoking cases according to the number of years since 
smoking cessation (in 5-year categories). After applying quality control data were available 
on 1,150 cases and 1,134 controls.
Quality control of GWAS datasets
Standard quality control was performed on all scans excluding individuals with low call rate 
(<90%) and extremely high or low heterozygosity (i.e. P<1.0×10−4), as well as all 
individuals evaluated to be of non-European ancestry (using the HapMap version 2 CEU, 
JPT/CHB and YRI populations as a reference; Supplementary Table 1). For apparent first-
degree relative pairs, we removed the control from a case-control pair; otherwise, we 
excluded the individual with the lower call rate.
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Replication series
To validate promising associations from meta-analysis were made use of in silico data and 
imputed genotypes from Harvard and deCODE GWAS datasets together with data from 
direct genotyping Heidelberg-EPIC, ICR, IARC and Toronto replication series.
Harvard For the Harvard Lung Cancer Susceptibility Study, details of participant 
recruitment have been described previously50. Replication was based on data derived from 
1,000 cases and 1,000 controls genotyped using Illumina Humanhap610-Quad arrays. Cases 
were patients aged >18 years, with newly diagnosed, histologically confirmed primary 
NSCLC. Controls were healthy non-blood-related family members and friends of patients 
with cancer or with cardiothoracic conditions undergoing surgery. The histological 
classification of lung tumors was performed by two staff pulmonary pathologists at the 
Massachusetts General Hospital according to ICD-O-3; Specifically, AD: 8140/3, 8250/3, 
8260/3, 8310/3, 8480/3 8560/3; LCC: 8012/3, 8031/3; SQ: 8070/3, 8071/3, 8072/3, 8074/3; 
and other NSCLC: 8010/3, 8020/3, 8021/3, 8032/3, 8230/3. Unqualified samples were 
excluded if they fit the following QC criteria: (i) overall genotype completion rates <95%; 
(ii) gender discrepancies; (iii) unexpected duplicates or probable relatives (based on pairwise 
identity by state value, PI_HAT in PLINK>0.185); (iv) heterozygosity rates >6 times the 
standard deviation from the mean; or (v) individuals evaluated to be of non-Caucasians 
(using the HapMap release 23 including JPT, CEPH, CEU and YRI populations as a 
reference). Unqualified SNPs were excluded when they fit the following QC criteria: (i) 
SNPs were not mapped on autosomes; (ii) SNPs had a call rate <95% in all GWAS samples; 
(iii) SNPs had MAF <0.01; or (iv) the genotype distributions of SNPs deviated from those 
expected by Hardy-Weinberg equilibrium (P<1.0×10−6). After applying these pre-specified 
quality controls genotype data were available for 984 cases and 970 controls.
deCODE The Icelandic lung cancer study has been described previously4. The primary 
source of information on the Icelandic lung cancer cases is the Icelandic Cancer Registry 
(ICaR) which covers the entire population of Iceland (http://www.cancerregistry.is). The 
sources of data in the ICaR are all pathology and hematology laboratories, all hospital 
departments and health care facilities in the country. ICaR registration is based on the ICD 
system and included information on histology (Systemized Nomenclature of Medicine, 
SNOMED). The ICaR registration also uses the ICD-O system which takes histology 
diagnosis into account. Over 94% of diagnoses in the ICaR have histological confirmation. 
According to the ICaR, Briefly, according to the ICaR a total of 4,252 lung cancer patients 
were diagnosed from January 1, 1955, to December 31, 2010. Recruitment of both prevalent 
and incident cases was initiated in 1998, the recruitment is ongoing and DNA samples from 
lung cancer cases are subjected to whole-genome genotyping as they are collected. The 
controls used in this study consisted of individuals from other GWASs, age and sex-matched 
to cases with no individual disease group accounting for >10% of all controls. Samples were 
assayed with the Illumina HumanHap300, HumanCNV370, HumanHap610, HumanHap1M, 
HumanHap660, Omni-1, Omni 2.5 or Omni Express bead chips at deCODE genetics. SNPs 
were excluded if they had (i) a yield <95%, (ii) MAF <1% in the population, (iii) deviation 
from Hardy-Weinberg equilibrium (HWE; P<10−6), (iv) inheritance error rate (>0.001) or 
(v) if there was a substantial difference in allele frequency between chip types (in which 
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case the SNP was removed from a single chip type if that resolved the difference, but if it 
did not then the SNP was removed from all chip types). All samples with a call rate of <97% 
were removed from the analysis. The Icelandic sample set is drawn from the Icelandic 
population, a small homogeneous founder population with almost no detectable population 
substructure. Thus there was no need adjust for such substructure in the association analysis. 
In addition, the comprehensive Icelandic genealogy database allowed us to exclude 
individuals not of Icelandic origin from the analysis. SNP genotypes were phased using the 
method of long range phasing51; for the HumanHap series of chips, 304,937 SNPs were 
used for long range phasing, whereas for the Omni series of chips 564,196 SNPs were used. 
An initial imputation step was carried out on each chip series separately to create a single 
harmonized, long-range phased genotype dataset consisting of 707,525 SNPs for 95,085 
Icelandic individuals. Two sets of genotypes were imputed into this dataset with methods 
previously described 52: (i) genotypes for about 38 million variants using the 1000 genomes 
phase I integrated variant set (v3) as training set, and (ii) genotypes for about 34 million 
variants identified in 2,230 whole genome sequenced Icelanders. The first set of imputed 
genotypes was used for replicating the association with variants in the 5p15.33, 9p21 and 
12q13.33 regions, using IMPUTE (v2.1.1)53 to perform the cases-control analysis. The 
second set was used when testing the relationship between K3326X, 999del5 genotypes and 
risk of different cancer types in the Icelandic population using a method that allowed 
including individuals that had not been chip typed, but for which genotype probabilities 
were imputed using methods of familial imputation51.
Heidelberg-EPIC comprised 1,253 EPIC-Heidelberg controls and 1,362 lung cancer cases 
from the Heidelberg lung cancer study recruited between 1994-1998 and 1996-2007, 
respectively. Details of the EPIC-Heidelberg controls and the Heidelberg lung cancer study 
have been previously described 54,55. All subjects were aged 18 years or older and 
information on lifestyle risk factors, medical and family history was collected through 
interviews based on standardised questionnaires. The EPIC Lung and the Heidelberg-EPIC 
studies were performed independently with no sample overlap with those analysed as part of 
the IARC-replication series. Histological classification of tumours was obtained from 
pathology reports, where it was recorded by staff pulmonary pathologist according to WHO. 
Blood samples from patients with malignant lung disease categorized as follows were 
included: AD, SCLC, NSCLC, LCC, carcinoid, mixed lung tumors, mixed without SCLC. 
The above EPIC Lung and the Heidelberg-EPIC studies were performed independently with 
no sample overlap. Genotypes for SNPs showed no significant departure from Hardy-
Weinberg equilibrium with the exception of rs13314271 in cases.
ICR-replication comprised 2,448 cases (1,664 male; mean age at diagnosis 71.8 years, SD 
6.7) with pathologically confirmed lung cancer ascertained through GELCAPS48 and 2,989 
controls (1,469 male, mean age at sampling 60.6 years, SD 12.0) collected through the 
National Study of Colorectal Cancer Genetics56 with no personal history of malignancy. 
Cases were sub-classified into histological subtypes based on ICD coding as described 
above (Study description: ICR-GWAS). Both cases and controls were British residents and 
had self-reported European Ancestry. The genotype distributions of genotypes for each of 
the SNPs typed in replication showed no significant departure from HWE.
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IARC-replication comprised three studies: (i) EPIC Lung2,57, a nested case control study 
performed within the EPIC (European Prospective Investigation into Cancer and Nutrition) 
prospective cohort totalling 1,119 lung cancer cases and 2,546 controls (matched 1-2 to 
cases for age, sex, centre, and time of recruitment), selected from eight of the 10 countries 
participating in EPIC (Sweden, Netherlands, UK, France, Germany, Spain, Italy and 
Norway); (ii) Szczecin case-control study32 a consecutive series of 849 incident lung cancer 
cases ascertained from the outpatient oncology clinic in the regional hospital of Szczecin 
between 2004-2007. The 1,072 controls were individuals without a diagnosed cancer or 
family history of cancer matched to cases by sex, age and region recruited via general 
medical practitioners; (iii) Moscow L2, 1,081 newly diagnosed lung cancer cases and 2,119 
controls recruited from three hospitals within the Moscow area of Russia between 2007 and 
2011. Information on lifestyle risk factors, medical and family history was collected from 
subjects by interview using a standard questionnaire. Cases were sub-classified into 
histological subtypes based on ICD-O3 coding as described above (Study description: 
IARC-GWAS). The genotype distributions of genotypes for each of the SNPs typed in 
replication showed no departure from HWE in each country/study series.
The Toronto study was conducted in the Great Toronto Area from 2008 to 2013. Lung 
cancer cases were recruited at the hospitals in the network of University of Toronto. 
Controls were randomly selected from individuals registered in the family medicine clinics 
databases, frequency matched with cases on age and sex. All subjects were interviewed and 
information on lifestyle risk factors, occupational history, medical and family history 
collected using a standard questionnaire. Tumours were centrally reviewed by the reference 
pathologist (a member of the IASLC committee) and a second pathologist in the University 
Health Network. If reviews conflicted, consensus was arrived at following discussion. 
Coding of histology was based on 2001 WHO/IASLC. After applying standardized quality 
control procedures and restricting to participants with self-reported European ancestry, data 
and samples were available on 1,084 cases and 966 controls. The genotype distributions of 
genotypes for each of the SNPs typed in replication showed no significant departure from 
HWE.
Replication genotyping
Genotyping of rs1519542, rs13314271, rs55731496, rs149423192, rs4592420, rs11571833, 
rs56084662 and rs17879961 was performed using either competitive allele-specific PCR 
KASPar chemistry (LGC, Hertfordshire, UK; UK replication series), Sequenom (Sequenom, 
Inc. San Diego, US; Toronto replication, Heidelberg-EPIC replication [rs1519542, 
rs55731496, rs149423192, rs4592420, rs11571833, rs56084662, rs17879961],) or Taqman 
(Carlsbad, CA; IARC-replication series, Heidelberg-EPIC replication [rs13314271]). All 
primers, probes and conditions used are available on request. Call rates for SNP genotypes 
were >95% in each of the replication series.
To ensure quality of genotyping in all assays, at least two negative controls and 1-10% 
duplicates (showing a concordance >99%) were genotyped at each centre. To exclude 
technical artefact in genotyping, at the ICR and IARC we performed cross-platform 
validation of 96 samples and sequenced a set of 96 randomly selected samples from each 
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case and control series to confirm genotyping accuracy. Assays were found to be performing 
robustly; concordance >99%.
Statistical and bioinformatic analysis
Data were imputed for all scans for over 10 million SNPs using data from the 1000 
Genomes Project (Phase 1 integrated release 3, March 2012) as reference, using IMPUTE2 
v2.1.153, MaCH58 v1.0 or minimac (version 2012.10.3)59 software (Supplementary Table 
1). Genotypes were aligned to the positive strand in both imputation and genotyping. 
Imputation was conducted separately for each scan in which prior to imputation each GWAS 
dataset was pruned to a common set of SNPs between cases and controls. As previously 
advocated we set thresholds for imputation quality to retain both potential common and rare 
variants for validation13,60. Specifically, poorly imputed SNPs defined by an RSQR<0.30 
with MaCH or an information measure Is<0.40 with IMPUTE2 were excluded from the 
analyses. Tests of association between imputed SNPs and lung cancer was performed under 
a probabilistic dosage model in SNPTEST v2.561, ProbABEL62, MaCH2dat v.12458 or glm 
function in R. Principle components generated using common SNPs were included in the 
analysis in order to limit the effects of cryptic population stratification that might cause 
inflation of test statistics. The association between each SNP and lung cancer risk was 
assessed by the Cochran-Armitage trend test. The adequacy of the case-control matching 
and possibility of differential genotyping of cases and controls were formally evaluated 
using quantile-quantile (Q-Q) plots of test statistics. Meta-analysis was undertaken using 
inverse-variance approaches. The inflation factor λ was based on the 90% least significant 
directly typed SNPs63. Odds ratios (ORs) and associated 95% confidence intervals (CIs) 
were calculated by unconditional logistic regression using R (v2.6), Stata v.10 (State 
College, Texas, US) and PLINK64 (v1.06) software. Cochran’s Q-statistic to test for 
heterogeneity and the I2 statistic to quantify the proportion of the total variation due to 
heterogeneity were calculated65. I2 values ≥75% are considered characteristic of large 
heterogeneity65. Additionally analyses stratified by histology, sex, age and smoking status 
(current, former, never) were performed. All statistical tests are two-sided.
The fidelity of imputation as assessed by the concordance between imputed and directly 
genotyped SNPs was examined in a subset of samples from the UK-GWAS, MDACC-
GWAS, IARC-GWAS and NCI-GWAS discovery series (Supplementary Table 3).
LD metrics were calculated in PLINK using 1000 genomes data and plotted using SNAP66. 
LD blocks were defined on the basis of HapMap recombination rate (cM/Mb) as defined 
using the Oxford recombination hotspots and on the basis of distribution of confidence 
intervals defined by Gabriel et al.67
Relationship between genotypes and smoking
To examine the relationship between rs11571833 (BRCA2 K3326X), rs17879961 (CHEK2 
I157T) and rs13314271 (TP63) genotype and cigarette consumption (cigarette per day)68 we 
made use of data on using 43,693 Icelandic subjects (including 34,850 chip typed 
individuals).
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Sequence analysis of BRCA2 in constitutional DNA
At the ICR targeted sequencing for c.6275delTT and c.4889C>G BRCA2 mutations was 
performed by Sanger implemented on an ABI3700 analyzer (Applied Biosystems; primer 
sequences and conditions available on request). Mutational analysis of the complete coding 
region of BRCA2 was based on exome sequencing data generated using Illumina TruSeq 
capture technology (Illumina, Inc, San Diego, CA 92122 USA). Analysis of Illumina 
HiSeq2000 (Illumina, Inc, San Diego, USA) sequence data from was performed using an in-
house pipeline based on the GATK tool kit.
At IARC Qiagen Generead (SABiosciences/Qiagen Hilde, Germany) was used to amplify 
the coding region of BRCA2 in rs11571833 heterozygotes. Following library preparation 
(New England Biolabs, Ipswich, MA, USA) sequencing was performed using an IonTorrent 
PGM desktop sequencer (Life Technologies, Guilford, San Francisco, CA). Genotypes were 
called using Ionsuite software. Sequence changes were referenced to Leiden Open Variation 
Database (LOVD2) and BReast CAncer IARC databases.
Analysis of TCGA data
The exomes of 243 LUSC and 338 LUAD TCGA individuals (Project Number #3230) were 
analyzed at IARC using an in-house pipeline based on the GATK tool set. Variant calls were 
annotated using ANNOVAR making use of use the NHLBI Exome Sequencing Project and 
1000 Genomes data.
Copy number variation—This was assessed from Human SNP Array 6.0 data. We 
retrieved level 3 TCGA data comprising normalized log2 ratios of the fluorescence 
intensities between the target sample and a reference sample. We included in our analysis 
only tumour-normal paired data. We considered a log2 ratio <−0.5 as reflecting loss, and a 
log2 ratio >0.5 reflecting gain. Annotation was performed adding the genes contained in 
each of the remaining segments using EnsEMBL databases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genome-wide P-values (−log10P, y axis) plotted against their respective chromosomal 
positions (x axis)
(a) All lung cancer, (b) AD and (c) SQ. Shown are the genomewide P-values (two-sided) 
obtained using the Cochran-Armitage trend test from analysis of 8.9 million successfully 
imputed autosomal SNPs in 11,348 cases and 15,861 controls from discovery phase. The red 
and blue horizontal lines represent the significance threshold of P=5.0×10−8 and 
P=5.0×10−6 respectively. Any region contains at least one association signal better than 
P=5.0×10−6 were selected for the in silico replication.
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Figure 2. Plot of the odds ratios of lung cancer associated with 13q13.1 (rs11571833 and 
rs56084662), 22q12.1 (rs17879961) and 3q28 (rs13314271) risk loci (a-l)
All lung cancer based on 21,594 lung cancer cases and 54,156 controls (a-d), SQ based on 
6,477 SQ and 53,333 controls (e-h) and AD based on 7,031 AD and 53,189 controls (i-l). 
Studies are weighted according to the inverse of the variance of the log of the OR calculated 
by unconditional logistic regression. Horizontal lines: 95% confidence intervals (95% CI). 
Box: OR point estimate; its area is proportional to the weight of the study. Diamond (and 
broken line): overall summary estimate, with confidence interval given by its width. 
Unbroken vertical line: at the null value (OR = 1.0).
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Figure 3. Regional plots of association results and recombination rates for the 13q13.1 in SQ (a), 
22q12.1 in SQ (b) and 3q28 susceptibility loci in AD (c)
SQ related panels (a, b) were based on 3,275 SQ and 15,038 controls from discovery phase; 
and AD related panel (c) was based on 3,442 AD and 14,894 controls from discovery phase. 
Association results of both genotyped (circles) and imputed (diamonds) SNPs in the GWAS 
samples and recombination rates for each locus: For each plot, −log10P values (y axis) of the 
SNPs are shown according to their chromosomal positions (x axis). The top genotyped SNP 
in each combined analysis is a large diamond and is labeled by its rsID. The color intensity 
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of each symbol reflects the extent of LD with the top genotyped SNP: white (r2=0) through 
to dark red (r2=1.0). Genetic recombination rates (cM/Mb), estimated using HapMap CEU 
samples, are shown with a light blue line. Physical positions are based on NCBI build 37 of 
the human genome. Also shown are the relative positions of genes and transcripts mapping 
to each region of association. Genes have been redrawn to show the relative positions; 
therefore, maps are not to physical scale.
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